Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan

Table 1 Demographic & baseline characteristics [Efficacy analysis (endoscopic evaluation: n = 38)]

Item		Subjects
		n	%
Age at baseline (yr)	20-39	0	0.0
	40-64	16	42.1
	≥ 65	22	57.9
Sex	Male	14	36.8
	Female	24	63.2
Diagnosis	Gastric ulcer	33	86.8
	Duodenal ulcer	3	7.9
	Gastric/duodenal ulcer	2	5.3
Ulcer history	Initial occurrence	15	39.5
	Reoccurrence	13	34.2
	Unknown	10	26.3
Prior history	No	28	73.7
	Yes	10	26.3
History of allergies	No	31	81.6
	Yes	5	13.2
	Unknown	2	5.3
Type of NSAID (duplicates included)	Diclofenac sodium	14	36.8
	Loxoprofen sodium	14	36.8
	Other	15	39.5
Anti-ulcer treatment before rabeprazole treatment (within 1 mo)	No	12	31.6
	Yes	26	68.4
Concomitant medication (not including NSAIDs)	No	5	13.2
	Yes	33	86.8
Endoscopic findings before start of treatment (ulcer size)	3 ≤ size < 10 mm	21	55.3
	10 ≤ size < 20 mm	13	34.2
	≥ 20 mm	4	10.5
Rabeprazole treatment duration	≤ 56 d	20	52.6
	> 56 d	18	47.4
Rabeprazole dosage	10 mg	24	63.2
	20 mg	12	31.6
	10 mg→20 mg	1	2.6
	20 mg→10 mg	1	2.6